Today #BoltBio reported financial results for the fourth quarter & full year 2024 and provided corporate updates. Learn more: bit.ly/4j0aMCs

I enjoyed being a part of this distinguished panel of speakers which included, Drs. Jimmy Li and Xiao(Michelle) Meng, during the ADC session at the Sino-American Pharmaceutical Professionals Association -Greater Philadelphia meeting (SAPA-GP). Chinese Antibody Society

"You can find the role models you are looking for." 2022 chemistry laureate Carolyn Bertozzi shares an important message to all who don't see themselves represented in mainstream science. Who is your role model? #WomenInScience

Excellent publication using AI and the biology of the HER2 ADC, SHR-1811. Nature Cancer AACR cell.com/cancer-cell/ab…

Today, we're presenting data from our next-generation Boltbody™ #ISACs targeting CEA and PD-L1 at #AACR25! We're encouraged by these early results and are excited about this compelling new approach to treat #cancer. Read our press release here: bit.ly/42D9Oqr

The FDA has granted Roche's TROP2 diagnostic device, VENTANA TROP2 (EPR20043) RxDx Device, a breakthrough designation. This is huge to help identify patients who respond to Dato-DXd. Roche AstraZeneca World ADC diagnostics.roche.com/us/en/news-lis…

Can machine learning/artificial intelligence increase the clinical success rates of oncology drugs? jackson-consulting-group.com/post/can-machi…

Join us today at 6:00am MT / 8:00am ET / 1:00pm BST for our (L)earnings Call focused on our business updates and financial results for our 2025 Q1. Questions may be submitted at: forms.gle/LYZwaVdPJidC7x… x.com/i/broadcasts/1…

Recursion, a leading AI drug developer, has dramatically trimmed their pipeline. BioPharma Dive Google AI AACR Recursion biopharmadive.com/news/recursion…

This is the first accurate reporting on why China is becoming a global leader in science and technology through investments to support the development of heir infrastructure. Perhaps US leaders should take note. youtube.com/live/I1PE8xRJ3…

The FDA has granted Abbvie's cMET ADC accelerated approval for NSCLC patients. AbbVie World ADC AACR ASCO fiercepharma.com/pharma/abbvie-…

Exciting News: We’re proud to share that our bispecific antibody has been approved in China for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) — a significant milestone for patients facing this

Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months. High activity irrespective of PDL1 expression. Same setting of ASCENT-03/04. Confirms the feeling that, in the future, we’ll treat mTNBC with frontline Trop2 ADCs. #ASCO25

Cheatsheet for SG vs Sac-TMT ADC properties and designs for various #ASCO25 presentations:

The once promising ADC Therapeutics is closing their UK site and laying off staff. @adctherapeutics fiercebiotech.com/biotech/adc-sh…

The TROP2 ADC, Datroway, earns FDA approval in previously treated EGFR mutant metastatic NSCLC patients with a 45% ORR and a DOR of 6.5 months from the pooled analysis. Daiichi Sankyo US National Cancer Institute AACR cancernetwork.com/view/dato-dxd-…

NIH announces end to funding for animal-only studies - Drug Discovery and Development share.google/FuYF2NSrAfKUjh… NIH National Cancer Institute AACR ASCO ESMO - Eur. Oncology

I will be hosting a session at the upcoming World ADC Summit on the lessons learned for ADC targets and new method to identify the next generation of ADC targets. I look forward to meeting everyone. If you plan to attend, reach out. World ADC app.ingo.me/q/zcyeo